Improving Lives Through

Diagnostic and
Therapeutic Solutions

AXIM’s proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions through laboratory-derived cannabinoid and oncological therapeutics.

Improving Lives Through

Diagnostic and
Therapeutic Solutions

AXIM’s proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions through laboratory-derived cannabinoid and oncological therapeutics.

COVID-19 TESTING

AXIM Biotechnologies has developed the first rapid (10-minute) point-of-care test that measures the concentration of neutralizing antibodies to COVID-19.

CLINICAL therapeutics

AXIM’s clinical therapeutic research focuses around an enzyme called “QSOX1” where the company hopes to bring a novel oncology drug to market 

CANCER dIAGNOSTICS

AXIM is in development of various “point-of-care” diagnostic testing products designed for the early detection of cancer

The Latest On Our Research

Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). AXIM’s NeuCovix is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis.

COVID Fighters Rewarded on Markets

By Baystreet The old adage, "he also serves who only sits and waits," is being severely tested these days with the impatience millions are feeling to see some sort of banishment of the deadly COVID-19. Thomas Edison’s statement “he also serves who hustles while he...

read more